Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 13/20 | 0.69 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 17/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.65 |
| ▸ | HDAC4 | P56524 | 8/20 | 0.65 |
| ▸ | HDAC7 | Q8WUI4 | 8/20 | 0.65 |
| ▸ | HDAC10 | Q969S8 | 8/20 | 0.65 |
| ▸ | HDAC11 | Q96DB2 | 8/20 | 0.65 |
| ▸ | HDAC9 | Q9UKV0 | 8/20 | 0.65 |
| ▸ | HDAC5 | Q9UQL6 | 8/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7739466 | 0.99 | HDAC1 (0.67) | HDAC1HDAC2HDAC6HDAC3HDAC8 | |
| SCHEMBL7740959 | 0.96 | HDAC1 (0.61) | HDAC1HDAC2HDAC6HDAC3HDAC8 | |
| SCHEMBL8115512 | 0.89 | HDAC6 (0.52) | HDAC1HDAC2HDAC6HDAC3HDAC8 | |
| SCHEMBL8107756 | 0.89 | HDAC6 (0.52) | HDAC1HDAC2HDAC6HDAC3HDAC8 | |
| SCHEMBL7740305 | 0.84 | ADCY6 (0.57) | HDAC1HDAC2HDAC6HDAC3HDAC8 | |
| SCHEMBL6385727 | 0.80 | HDAC6 (1.00) | HDAC1HDAC2HDAC6HDAC3HDAC8 | |
| SCHEMBL6387051 | 0.80 | HDAC6 (1.00) | HDAC1HDAC2HDAC6HDAC3HDAC8 | |
| SCHEMBL7734900 | 0.79 | ADCY6 (0.52) | HDAC6 | |
| SCHEMBL6389005 | 0.78 | HDAC6 (0.97) | HDAC1HDAC2HDAC6HDAC3HDAC8 | |
| SCHEMBL7734913 | 0.78 | HDAC6 (0.51) | HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050119305-A1 | Il-6 production inhibitors | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-02 | — | — | US | claimed |
| US-6420427-B1 | PREVENTION AND/OR TREATMENT OF RHEUMATOID DISEASES, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS, INTERSTITIAL NEPHRITIS, ARTERIOSCLEROSIS, PULMONARY EMPHYSEMA, CIRRHOSIS, CORNEA INJURY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | claimed |
| EP-1024134-A1 | AMINOBUTANOIC ACID DERIVATIVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2000-08-02 | — | — | EP | claimed |
| US-20050119305-A1 | Il-6 production inhibitors | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-02 | — | — | US | disclosed |
| US-6420427-B1 | PREVENTION AND/OR TREATMENT OF RHEUMATOID DISEASES, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS, INTERSTITIAL NEPHRITIS, ARTERIOSCLEROSIS, PULMONARY EMPHYSEMA, CIRRHOSIS, CORNEA INJURY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| EP-1024134-A1 | AMINOBUTANOIC ACID DERIVATIVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2000-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119305-A1 | Il-6 production inhibitors | IL6, IL6ST, PADI6 | HDAC1 1343/4885HDAC2 2783/4885HDAC6 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.